USA: People taking GLP-1 receptor agonists may be more likely to experience nail problems, with nail detachment reported more than four times as often as among comparable individuals with obesity or type 2 diabetes who were not using these medications, according to findings presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026.

The multinational study is the first controlled investigation to specifically examine the potential association between GLP-1 receptor agonist use and nail health. Researchers compared 575 GLP-1 receptor agonist users with 1,329 individuals with obesity and/or type 2 diabetes who had never used these medications. Participants were recruited from France, the United States, Brazil, and Mexico.
GLP-1 receptor agonists are increasingly prescribed for type 2 diabetes and obesity. While their effects on metabolic health and weight are well established, their potential dermatological effects, particularly on nails, have received considerably less attention.
The analysis found:
  • 66% of GLP-1 users reported at least one nail disorder, compared with 53% of controls.
  • Nail detachment was reported by 39% of GLP-1 users versus 9% of controls, representing more than a fourfold difference.
  • Nail discolouration occurred in 46% of GLP-1 users, compared with 17% of controls.
  • The differences remained significant when researchers specifically examined participants who had experienced weight loss, suggesting that weight reduction alone may not fully account for the nail changes.
  • After accounting for dermatological conditions and nutritional deficiencies, nail detachment and discolouration remained approximately two to three times more frequent among GLP-1 users.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” study author Dr Charles Taïeb, said in a press release. He noted that the findings demonstrate an association but do not establish that GLP-1 treatment itself is responsible for the changes.
The researchers highlighted an important limitation: about half of GLP-1 users reported nail problems before beginning treatment. Adjustment for existing dermatological conditions and nutritional deficiencies also weakened some of the observed associations.
A companion analysis involving the same participants found that hair and scalp abnormalities were also more frequent among GLP-1 users. Unusual hair loss was reported in 50% of users compared with 34% of controls, while reduced hair volume or density affected 42% versus 19%. Hair loss that began after treatment initiation occurred in 26% versus 12%, and scalp redness was approximately three times more common among users.
Researchers noted that hair loss frequently occurred alongside scalp symptoms such as itching, redness and scaling, raising the possibility of an inflammatory component beyond hair shedding associated with rapid weight loss.
The investigators stressed that these findings should prompt clinical awareness rather than discontinuation of treatment. Patients developing nail changes, hair loss or scalp symptoms should discuss them with their physician rather than stopping GLP-1 therapy independently.
The study was cross-sectional and based on patient-reported symptoms, limiting the ability to establish causality or determine when the changes began. Future prospective studies will follow patients from treatment initiation with standardized dermatological assessments and biological monitoring to clarify the causes, timing and reversibility of these changes.
Reference:
Piraccini BM et al. Association between GLP-1 receptor agonists and nail disorders: results from a multinational casecontrol study. EADV Congress, 30 September – 3 October, 2026.


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .